Fibroblast Growth Factor 21 in Gestational Diabetes Mellitus and Type 2 Diabetes Mellitus.
Journal
Journal of diabetes research
ISSN: 2314-6753
Titre abrégé: J Diabetes Res
Pays: England
ID NLM: 101605237
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
08
2022
revised:
02
10
2023
accepted:
03
10
2023
medline:
2
11
2023
pubmed:
23
10
2023
entrez:
23
10
2023
Statut:
epublish
Résumé
Women who develop GDM present a metabolic condition similar to that found in type 2 diabetes, characterized by impaired insulin response. Due to similar pathophysiologic mechanisms found between type 2DM and GDM, there is a great interest in finding markers that will lead to the understanding of a possible common origin to both diseases. The aim of this study was to determine serum FGF21 levels in 2DM and GDM and its correlation with selected metabolic parameters. The study included 54 2DM patients and 52 nondiabetic individuals (control group 1) as well as 74 GDM women and 32 healthy pregnant controls (control group 2). Serum FGF21 was determined by enzyme-linked immunosorbent assay (ELISA), in all groups, and correlated with biochemical parameters of glucose metabolism and insulin resistance (HbA1c, HOMA index, TG, and HDL cholesterol). FGF21 concentration was significantly higher in 2DM as compared with control group 1 ( Serum FGF21 levels were significantly higher in 2DM patients than those without diabetes. Moreover, serum FGF21 levels were associated with selected metabolic parameters, suggesting that it may play acrolein glucose and lipid metabolism.
Identifiants
pubmed: 37869250
doi: 10.1155/2023/4024877
pmc: PMC10590262
doi:
Substances chimiques
fibroblast growth factor 21
0
Fibroblast Growth Factors
62031-54-3
Insulin
0
Blood Glucose
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4024877Informations de copyright
Copyright © 2023 Katarzyna Gawlik et al.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to declare.
Références
Metabolism. 2010 Jan;59(1):33-7
pubmed: 19699495
Am J Physiol Endocrinol Metab. 2023 May 1;324(5):E409-E424
pubmed: 36629821
Children (Basel). 2022 Aug 09;9(8):
pubmed: 36010082
PLoS One. 2017 Jun 23;12(6):e0179647
pubmed: 28644881
J Clin Endocrinol Metab. 2016 Dec;101(12):4886-4894
pubmed: 27662438
Cureus. 2021 Sep 4;13(9):e17723
pubmed: 34659937
Horm Metab Res. 2022 Apr;54(4):203-211
pubmed: 35413740
Acta Endocrinol (Buchar). 2016 Jul-Sep;12(3):257-261
pubmed: 31149098
Int J Mol Sci. 2020 Feb 12;21(4):
pubmed: 32059381
Med Res Rev. 2016 Jul;36(4):672-704
pubmed: 27031294
Clin Endocrinol (Oxf). 2019 Jan;90(1):47-55
pubmed: 30346647
Cardiovasc Diabetol. 2015 Jun 06;14:72
pubmed: 26047614
J Clin Invest. 2005 Jun;115(6):1627-35
pubmed: 15902306
Int J Mol Sci. 2020 Aug 16;21(16):
pubmed: 32824322
Diabetes Res Clin Pract. 2010 Jul;89(1):52-7
pubmed: 20452080
J Med Invest. 2014;61(1-2):28-34
pubmed: 24705745
Front Endocrinol (Lausanne). 2021 Nov 29;12:795520
pubmed: 34912302
Front Cardiovasc Med. 2021 Mar 31;8:655575
pubmed: 33869312
Acta Endocrinol (Buchar). 2017 Jul-Sep;13(3):278-281
pubmed: 31149188
J Mol Cell Biol. 2016 Apr;8(2):110-9
pubmed: 26993043
Diabetes Care. 2013 Jan;36(1):145-9
pubmed: 22933429
Endocr J. 2021 Mar 28;68(3):345-352
pubmed: 33162410
BMJ Open Diabetes Res Care. 2021 Jan;9(1):
pubmed: 33397671
PeerJ. 2022 Jan 19;10:e12755
pubmed: 35111398
Clin Endocrinol (Oxf). 2017 Jan;86(1):37-43
pubmed: 27611701
EBioMedicine. 2021 Jan;63:103202
pubmed: 33421947
Diabetes. 2010 Nov;59(11):2781-9
pubmed: 20682689
J Diabetes Res. 2019 Nov 19;2019:5320156
pubmed: 31828161
Int J Mol Sci. 2020 Aug 30;21(17):
pubmed: 32872570
PLoS One. 2013 Nov 19;8(11):e81190
pubmed: 24260557
Horm Mol Biol Clin Investig. 2020 Mar 13;41(2):
pubmed: 32167928